clinical trial · NCT07076706
Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
Beijing Dayspring Pharmaceutical Technology Co., Ltd·phase2·completed·n = 110
Male Pattern of Hair Loss, Androgenic AlopeciaAndrogenetic Alopecia (AGA)minoxidil + finasterideminoxidil + finasteridePlacebo foam
brief summary
The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety of CG2001 at the target dose.
started
Dec 5, 2024
primary completion
Aug 26, 2025
completion
Sep 23, 2025
last updated
Mar 3, 2026
official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol